| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Citadel Technologies is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tanis Technical is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.